BioSpace News Archive

Active Biotech provides status update of its clinical naptumomab project

Active Biotech provided a status update of its leading candidate drug naptumomab, developed together with the company’s partner NeoTX.

July 5, 2021
·
2 min read
Lexaria Announces Voluntary Delisting from the Canadian Securities Exchange to Concentrate Trading on the Nasdaq Capital Markets

Lexaria Bioscience Corp., a global innovator in drug delivery platforms announces that on June 30, 2021 it made a request to voluntarily delist its common shares from the Canadian Securities Exchange.

July 5, 2021
·
4 min read
Valneva to Host Symposium on COVID-19 and Chikungunya Vaccine Candidates at 31st European Congress of Clinical Microbiology & Infectious Diseases

ValnevaSE announced it will host a virtual symposium titled, “Developing new vaccines to protect against infectious diseases at home and abroad” on July 9, 2021 at 14:15 CEST at the 31st European Congress of Clinical Microbiology & Infectious Diseases.

July 5, 2021
·
6 min read
Policy

Government of Canada funds three new projects to encourage COVID-19 vaccination in Canada

The Honourable Patty Hajdu, Minister of Health, announced three new projects receiving funding through the Immunization Partnership Fund to support vaccination efforts across Canada.

July 5, 2021
·
4 min read
Drug Development

Antengene Announces Acceptance of IND Application in China for the Phase II Clinical Trial of Single-Agent Selinexor for the Treatment of Myelofibrosis (MF)

Antengene Corporation Limited recently announced that China’s National Medical Products Administration has accepted the Investigational New Drug application for single agent selinexor, a first-in-class orally available Exportin 1 inhibitor, for the treatment of patients with myelofibrosis in China.

July 5, 2021
·
6 min read
Business

Innovent and Laekna Therapeutics Enter a Partnership Agreement to Co-Develop Combination Therapy of Sintilimab and Afuresertib in Clinical Studies in China

Innovent Biologics, Inc. and Laekna Therapeutics Shanghai Co., Ltd. jointly announced they have entered into a collaboration agreement to evaluate the combination of Innovent’s PD-1 inhibitor sintilimab and Laekna’s pan-AKT kinase inhibitor afuresertib.

July 5, 2021
·
10 min read
Sartorius Stedim Biotech provides preliminary first-half financial key figures and raises forecast for 2021

For the first six months ended June 30, the company expects revenue growth to be approximately 61% in constant currencies with an underlying EBITDA margin1 in the range of 36.0 to 36.5%.

July 5, 2021
·
2 min read
Sartorius provides preliminary first-half financial key figures and raises forecast for 2021

Sartorius announces that it expects strong first–half performance and raises its forecast for the full year of 2021.

July 5, 2021
·
3 min read